Autoimmune Diseases
Welcome,         Profile    Billing    Logout  
 293 Companies   490 Products   490 Products   199 Mechanisms of Action   25 Trials   7787 News 


«12...5152535455565758596061...156157»
  • ||||||||||  atacicept (VT-001) / Vera Therap
    Enrollment closed, Trial primary completion date:  ADDRESS II: Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus (clinicaltrials.gov) -  Nov 11, 2015   
    P2b,  N=306, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Mar 2016
  • ||||||||||  New trial:  Post-transfusion Platelet Count (clinicaltrials.gov) -  Nov 10, 2015   
    P=N/A,  N=65, Not yet recruiting, 
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date, IO biomarker:  Consequences of Anti-interleukin 6 Immunotherapy Treatment for Rheumatoid Arthritis on Periodontium (clinicaltrials.gov) -  Nov 10, 2015   
    P4,  N=16, Terminated, 
    Initiation date: Aug 2009 --> Jan 2009 N=47 --> 16 | Recruiting --> Terminated | Trial primary completion date: Sep 2015 --> Jun 2015; as the recruitment rate was very low, a futility study was conducted and it was decided to discontinue inclusions
  • ||||||||||  Orencia (abatacept) / BMS
    Enrollment change:  Methotrexate-Inadequate Response Study (clinicaltrials.gov) -  Nov 9, 2015   
    P3,  N=2492, Completed, 
    Trial primary completion date: Jul 2016 --> Mar 2017 N=1482 --> 2492
  • ||||||||||  PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
    Trial primary completion date:  Protection Against Pneumococcal Infection in Children With T1DM (clinicaltrials.gov) -  Nov 9, 2015   
    P4,  N=50, Recruiting, 
    N=1482 --> 2492 Trial primary completion date: Oct 2014 --> Dec 2016
  • ||||||||||  Trial completion, Trial primary completion date:  Hybrid Artificial Pancreas in Home Setting (clinicaltrials.gov) -  Nov 8, 2015   
    P2,  N=36, Completed, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Jun 2015
  • ||||||||||  BioChaperone glargine/lispro (insulin glargine/insulin lispro) / Adocia
    Trial completion:  Postprandial Blood Glucose Control With BioChaperone (clinicaltrials.gov) -  Nov 8, 2015   
    P1,  N=28, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Jun 2015 Recruiting --> Completed
  • ||||||||||  Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
    Trial primary completion date:  Duration of Immune Response to Influenza Vaccination in Patients With RA (clinicaltrials.gov) -  Nov 6, 2015   
    P4,  N=90, Active, not recruiting, 
    Trial primary completion date: Mar 2019 --> Nov 2019 Trial primary completion date: Sep 2015 --> Dec 2015
  • ||||||||||  Trial primary completion date, HEOR:  Factors Associated With Biologic DMARD Switching (clinicaltrials.gov) -  Nov 6, 2015   
    P=N/A,  N=4099, Active, not recruiting, 
    N=40 --> 80 Trial primary completion date: Feb 2015 --> Nov 2015
  • ||||||||||  Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine) / UniQuest
    Enrollment open, Trial primary completion date:  Long-term Immunogenicity of a HPV Vaccine in SLE (clinicaltrials.gov) -  Nov 5, 2015   
    P=N/A,  N=100, Recruiting, 
    Recruiting --> Terminated; Lack of funding Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2015 --> Mar 2016
  • ||||||||||  ZB-168 / Zura Bio
    Trial termination, Trial primary completion date:  A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS) (clinicaltrials.gov) -  Nov 5, 2015   
    P1,  N=60, Terminated, 
    Trial primary completion date: Dec 2015 --> Jun 2016 Active, not recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Jan 2016; This study terminated on April 8, 2015 due to a corporate decision and not related to the safety or efficacy of the protocol.
  • ||||||||||  Lantus (insulin glargine) / Sanofi, Lusduna (insulin glargine biosimilar) / Samsung
    Trial initiation date:  A Study of the Safety and Efficacy of MK-1293 Compared to Lantus (clinicaltrials.gov) -  Nov 5, 2015   
    P3,  N=500, Active, not recruiting, 
    Active, not recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Jan 2016; This study terminated on April 8, 2015 due to a corporate decision and not related to the safety or efficacy of the protocol. Initiation date: Feb 2014 --> Oct 2013
  • ||||||||||  Trial termination, Trial primary completion date:  An ACT Based Application for Young People With Type 1 Diabetes (clinicaltrials.gov) -  Nov 3, 2015   
    P=N/A,  N=116, Terminated, 
    Initiation date: Feb 2014 --> Oct 2013 Recruiting --> Terminated | Trial primary completion date: Apr 2016 --> Nov 2015; No uptake from potential participants